SAB Biotherapeutics (SABSW) Accumulated Depreciation (2020 - 2025)
Historic Accumulated Depreciation for SAB Biotherapeutics (SABSW) over the last 6 years, with Q3 2025 value amounting to $16.8 million.
- SAB Biotherapeutics' Accumulated Depreciation rose 2145.64% to $16.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.8 million, marking a year-over-year increase of 2145.64%. This contributed to the annual value of $14.6 million for FY2024, which is 4703.52% up from last year.
- Latest data reveals that SAB Biotherapeutics reported Accumulated Depreciation of $16.8 million as of Q3 2025, which was up 2145.64% from $16.1 million recorded in Q2 2025.
- In the past 5 years, SAB Biotherapeutics' Accumulated Depreciation registered a high of $16.8 million during Q3 2025, and its lowest value of $3.2 million during Q4 2021.
- For the 5-year period, SAB Biotherapeutics' Accumulated Depreciation averaged around $10.2 million, with its median value being $10.9 million (2023).
- Per our database at Business Quant, SAB Biotherapeutics' Accumulated Depreciation skyrocketed by 9498.42% in 2022 and then skyrocketed by 2145.64% in 2025.
- Quarter analysis of 5 years shows SAB Biotherapeutics' Accumulated Depreciation stood at $3.2 million in 2021, then skyrocketed by 94.98% to $6.3 million in 2022, then soared by 57.87% to $9.9 million in 2023, then surged by 47.04% to $14.6 million in 2024, then increased by 15.42% to $16.8 million in 2025.
- Its Accumulated Depreciation was $16.8 million in Q3 2025, compared to $16.1 million in Q2 2025 and $15.3 million in Q1 2025.